Trial Search Results

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seattle Genetics, Inc.

Collaborator: Millennium Pharmaceuticals, Inc.

Intervention(s):

  • Drug: brentuximab vedotin
  • Drug: doxorubicin
  • Drug: prednisone
  • Drug: vincristine
  • Drug: cyclophosphamide

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with newly diagnosed, CD30-positive mature T-cell lymphomas

   - Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm
   by CT

   - Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

Exclusion Criteria:

   - History of another primary invasive malignancy that has not been in remission for at
   least 3 years

   - Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative
   disorders and lymphomas or mycosis fungoides

   - History of progressive multifocal leukoencephalopathy (PML)

   - Cerebral/meningeal disease related to the underlying malignancy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting